Shares of Sarepta Therapeutics climbed early Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
Source: https://www.marketwatch.com/story/pfize ... topstories
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
